MRC IAA 2021 University of Oxford
Lead Research Organisation:
University of Oxford
Department Name: Paediatrics
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Impact Acceleration Accounts is a key part of MRC's translational research strategy and provides annual awards to institutions to flexibly support a portfolio of translational research projects. MRC IAA is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept and to rapidly de-risk projects across the whole translational pathway so that they become competitive for substantial funding for development.
Organisations
People |
ORCID iD |
Matthew Wood (Principal Investigator) |
Description | HLA-E targeted T cell receptor therapy for Acute Myeloid Leukaemia (G |Gillespie and A McMichael) |
Amount | £73,070 (GBP) |
Organisation | Medical and Life Sciences Translational Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 07/2023 |
Description | MedTech SuperConnector |
Amount | £20,000 (GBP) |
Organisation | MedTech SuperConnector |
Sector | Private |
Country | United Kingdom |
Start | 01/2023 |
End | 06/2023 |
Description | TransNAT: Transforming delivery, safety and efficacy of nucleic acid therapeutics: from intracellular uptake to targeting brain and muscle. |
Amount | £8,000,000 (GBP) |
Funding ID | MR-X008029-1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2022 |
End | 10/2025 |
Title | DNA ASSEMBLY |
Description | The invention relates to a nucleic acid for use in DNA assembly, wherein the nucleic acid comprises at least one methylation-protectable restriction element, the methylation-protectable restriction element comprising: a restriction enzyme recognition sequence that is recognised by a restriction enzyme that cleaves outside of the recognition sequence; and a DNA methylase recognition sequence, wherein the restriction enzyme recognition sequence and the DNA methylase recognition sequence overlap such that the base modified by the DNA methylase lies within the restriction enzyme recognition sequence, wherein the DNA methylase recognition sequence is not identical to or enclosed by the restriction enzyme recognition sequence, and wherein the DNA methylase recognition sequence does not overlap with the sequence that would form the overhang end sequence generated by the restriction enzyme. The invention further relates to asscociated methods and kits. |
IP Reference | WO2018203056 |
Protection | Patent / Patent application |
Year Protection Granted | 2018 |
Licensed | Commercial In Confidence |
Impact | n/k |
Title | UNIVERSAL DNA ASSEMBLY |
Description | The invention relates to a nucleic acid comprising at least one methylation-protectable restriction element, the methylation-protectable restriction element comprising: (i) a type IIS restriction enzyme recognition sequence, or a partial type IIS restriction enzyme recognition sequence, that is recognised by a type IIS restriction enzyme that cleaves outside of the recognition sequence; (ii) a DNA methylase recognition sequence that is recognised and methylated by a DNA methylase, wherein the DNA methylase recognition sequence is identical to, or is encompassed within, the type IIS restriction recognition sequence, such that methylation of the nucleic acid by the DNA methylase methylates the type IIS restriction enzyme recognition sequence and protects the nucleic acid from cleavage by the type IIS restriction enzyme; and (iii) a recognition sequence for a sequence-specific DNA-binding protein, wherein the recognition sequence is positioned such that the binding of the sequence-specific DNA-binding protein overlaps with the DNA methylase recognition sequence such that binding of the sequence-specific DNA-binding protein is capable of preventing methylation of the type IIS restriction enzyme recognition sequence by the DNA methylase such that it is not protected from cleavage by the type IIS restriction enzyme. The invention further relates to associated methods of nucleic acid assembly. |
IP Reference | WO2020201434 |
Protection | Patent / Patent application |
Year Protection Granted | 2020 |
Licensed | Commercial In Confidence |
Impact | n/k |